In the Swedish pharmaceutical industry, there were 9 M&A deals announced in Q2 2024, worth a total value of $1bn, according to GlobalData’s Deals Database. The $1bn acquisition of Calliditas Therapeutics by Asahi Kasei was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Sweden increased by 43378% in Q2 2024 compared with the previous quarter’s total of $2.3m. Related deal volume increased by 50% in Q2 2024 versus the previous quarter and was 80% higher than in Q2 2023.
The top-ranked financial advisors supporting these M&A deals in Sweden in H1 2024 were Lazard; Eminova Partners Corporate Finance; Goldman Sachs Group with 2, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Sweden in H1 2024 were Bird & Bird; Bredin Prat & Associates; Cleary Gottlieb Steen & Hamilton with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2024 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.